ELICIO THERAPEUTICS, INC.

451 D Street, 5^th Floor

Boston, MA 02210

June 7, 2024

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Jessica Dickerson, Office of Life Sciences

Re:	Elicio Therapeutics, Inc.
	Registration Statement on Form S-3
	Filed June 3, 2024
	File No. 333-279925 (the “Registration Statement”)
	Acceleration Request

Ladies and Gentlemen:

In accordance with Rule 461 promulgated under the Securities Act of 1933, as amended, Elicio Therapeutics, Inc. (the “Registrant”) hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date and time of the above-referenced Registration Statement to Tuesday, June 11, 2024, at 4:00 p.m., Eastern Time, or as soon as thereafter practicable.

The cooperation of the staff in meeting the timetable described above is very much appreciated.

Please contact Daniel Bagliebter of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, at (212) 692-6856 with any questions regarding this request.

Very truly yours,

ELICIO THERAPEUTICS, INC.

/s/ Robert Connelly

Robert Connelly

Chief Executive Officer

cc:	Elicio Therapeutics, Inc.
	Megan Filoon
	Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
	William C. Hicks
	Daniel Bagliebter